ADTX

Aditxt Inc

0.0021

Jun 26 • 03:59PM ET -0.0002 (-8.70%)

Healthcare Biotechnology USA Nano NASD

Jun 25, 4:55 AMNasdaq panel rejects Aditxt appeal, orders ADTX delisting over bid-price and stockholders’ equity deficiencies

Peers: APRE BCDA BIVI CALC CVM GOVX KAPA KPRX LNAI NEUP

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-204009.52	Insider Own	1.45%	Shs Outstand	0.82M	Perf Week	-79.00%
Market Cap	2.10M	Forward P/E	-	EPS next Y	-	Insider Trans	-10.71%	Shs Float	0.41M	Perf Month	-98.98%
Enterprise Value	5.60M	PEG	-	EPS next Q	-	Inst Own	0.09%	Short Float	68.66%	Perf Quarter	-99.99%
Income	-53.34M	P/S	209.56	EPS this Y	-	Inst Trans	2.42%	Short Ratio	0.00	Perf Half Y	-100.00%
Sales	0.01M	P/B	-	EPS next Y	-	ROA	-230.24%	Short Interest	0.28M	Perf YTD	-100.00%
Book/sh	-861.43	P/C	7.76	EPS next 5Y	-	ROE	-576.19%	52W High	44422.56 -100.00%	Perf Year	-100.00%
Cash/sh	0.00	P/FCF	-	EPS past 3/5Y	99.40% -290.23%	ROIC	-	52W Low	- -	Perf 3Y	-100.00%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-84.93% -	Gross Margin	-1736.30%	Volatility	211.21% 93.04%	Perf 5Y	-100.00%
Dividend TTM	-	EV/Sales	559.56	EPS Y/Y TTM	99.99%	Oper. Margin	-127821.37%	ATR (14)	0.30	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.05	Sales Y/Y TTM	-74.09%	Profit Margin	-372062.41%	RSI (14)	13.52	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.06	EPS Q/Q	99.60%	SMA20	-94.81%	Beta	1.01	Target Price	14888880000.00
Payout	-	Debt/Eq	-	Sales Q/Q	1094.40%	SMA50	-99.92%	Rel Volume	0.35	Prev Close	0.00
Employees	26	LT Debt/Eq	-	Earnings	-	SMA200	-100.00%	Avg Volume	386.63M	Price	0.00
IPO	Jun 30, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	- 120.59%	Trades		Volume	135,771,321	Change	-8.70%

Jun-25-26 04:06AM	ADTX Stock Loses Nasdaq Listing After Seven Reverse Splits Fail To Restore Compliance: Why Is Retail Still Bullish? (Stocktwits) -75.79%
Jun-23-26 01:29AM	ADTX Stock Surges 40% Overnight: New 10% Holder Emerges After Aditxts Ignite Proteomics SPAC Deal (Stocktwits) +117.19%
Jun-11-26 04:34AM	ADTX Stock Rockets 90% Premarket: What's Fueling Rebound After A Record 22-Day Selloff? (Stocktwits) -29.73%
Jun-10-26 06:43AM	Aditxt and Ignite announce merger plans with strategic partner (Pharmaceutical Business Review) -35.99%
Jun-09-26 12:47PM	Why Is ADTX Stock In Spotlight Today? (Stocktwits) -42.08%
07:45AM	Loading…
07:45AM	Aditxt Signed Definitive Agreement Valuing Ignite Proteomics at Approximately $150 Million (Business Wire)
Jun-08-26 08:15AM	Ignite Proteomics Announces Prospective 10,000-Patient Oncology Registry to Evaluate Functional Proteomics in Cancer Therapy Selection (Business Wire) -19.65%
Jun-01-26 08:15AM	Aditxt, Inc. Appoints Jeffrey M. Busch as Interim Chief Executive Officer; Founder and Former CEO of $1B NYSE Enterprise Which Delivered ~8.5% Dividends to Shareholders (Business Wire)
May-14-26 08:15AM	Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-27 Reverse Stock Split Effective at the Open of Trading on May 18, 2026 (Business Wire) -20.67%
Apr-27-26 10:30AM	BC-Most Active Stocks (Associated Press) -11.89%
Apr-20-26 08:15AM	Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics' RPPA Platform for T-DXd (Enhertu) Therapy in Metastatic Breast Cancer Patients (Business Wire) -20.10%
Mar-19-26 08:15AM	Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer (Business Wire) -11.35%
Mar-13-26 08:15AM	Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection (Business Wire) -37.02%
Mar-05-26 08:30AM	Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026 (Business Wire) -8.58%
Nov-18-25 08:00AM	Aditxt Provides Updates on its Growth Vision for bitXbio, Planned Digital Asset Treasury, Pearsanta's Planned IPO, And Evofem's Plan to Regain a National Listing (Business Wire)
04:30PM	Loading…
Oct-29-25 04:30PM	Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025 (Business Wire) -12.53% -40.61%
Oct-27-25 08:30AM	Aditxt Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global Market (Business Wire) -9.81%
Oct-20-25 04:19PM	Evofem Announces Voting Results from Special Meeting of Stockholders (PR Newswire) +5.21% -14.28%
Sep-11-25 09:18AM	Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms (PR Newswire) +8.96%
Sep-09-25 09:28AM	Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting (PR Newswire) +16.14%
Aug-25-25 09:15AM	Aditxt's Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030 (Business Wire)
Aug-21-25 08:56AM	Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law (PR Newswire)
Aug-14-25 08:46AM	Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update (PR Newswire)
Aug-11-25 08:30AM	Aditxt and Crypto.com Sign Agreement for Custodial Crypto Account, Announce ADTX Share Access on Crypto.com as Part of the Larger bitXbio Initiative (Business Wire) -5.04%
Aug-05-25 08:46AM	Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference (PR Newswire) -9.02%
Jul-29-25 09:00AM	Aditxts Subsidiary, Pearsanta, Inc. Engages Spartan Capital as Lead Underwriter for its Planned IPO Intending to Drive Clinical Validation and Commercial Rollout of Its Mitomic Platform Technology for Early Detection of Cancers and Other Diseases (Business Wire) -5.74%
Jul-24-25 08:15AM	Aditxt's Subsidiary Pearsanta Receives an Invitation to Submit Full Proposal for the U.S. Department of Defense Pilot Award for the Development of its Mitomic Ovarian Test (Business Wire)
Jul-22-25 08:15AM	Aditxt to Present at Wall Street Reporter's Next Super Stock Livestream Today July 22, 2025, at 1 p.m. ET (Business Wire) +5.08%
Jul-15-25 09:12AM	Phexxi -- A Non-Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary Mommy (PR Newswire)
Jul-07-25 08:15AM	Aditxt Unveils bitXbio: A Bitcoin-Backed Treasury Strategy Designed to Accelerate Biotech Commercialization (Business Wire) -8.94%
08:15AM	Loading…
Jun-26-25 08:15AM	Aditxt to Present at Wall Street Reporter's NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ET (Business Wire)
Jun-09-25 08:15AM	Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors (Business Wire)
Jun-05-25 08:15AM	Saundra Pelletier, Evofem Biosciences' CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6 (Business Wire) -7.69%
May-19-25 08:00AM	Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc. (GlobeNewswire) +5.42%
08:00AM	Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics (Business Wire)
May-02-25 09:00AM	Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt, and Dr. Friedrich Kapp, Co-CEO of Adimune, to Discuss Progress of Lead Therapeutic Candidate ADI-100 (Business Wire)
Apr-17-25 09:08PM	KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials (Business Wire) +13.64% -10.80%
09:03PM	KILL Dr. Charles Howe of the Mayo Clinics Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxts Subsidiary Adimune (Business Wire)
08:15AM	Dr. Charles Howe of the Mayo Clinics Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxts Subsidiary Adimune (Business Wire)
Apr-16-25 08:15AM	Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025 (Business Wire) -8.71%
Apr-14-25 08:15AM	Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials (Business Wire) -13.19%
Apr-11-25 08:15AM	Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements (Business Wire)
Apr-10-25 09:24AM	Why Aditxt Inc. (ADTX) Went Down On Thursday? (Insider Monkey)
Apr-09-25 08:15AM	Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements (Business Wire) -8.81%
Apr-02-25 08:17AM	Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025 (GlobeNewswire) +10.62%
08:15AM	Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025 (Business Wire)
Mar-28-25 08:15AM	Upcoming Aditxt Weekly Update to Highlight Pearsanta's Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection (Business Wire) -18.90%
Mar-24-25 08:30AM	Evofem Reports Fourth Consecutive Year of Net Sales Growth (PR Newswire) -25.55%
08:15AM	Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk (Business Wire)
Mar-18-25 07:22AM	Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update (GlobeNewswire) +71.62%
Mar-17-25 08:15AM	Aditxt Provides Business Status Overview and Announces Launch of Aditxt Weekly Update Starting Friday, March 21, 2025 (Business Wire) -13.03%
Mar-12-25 04:15PM	Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-250 Reverse Stock Split Effective at the Open of Trading on March 17, 2025 (Business Wire) -5.33% -41.20%
Mar-06-25 08:15AM	Aditxt Subsidiary Adimune to Ship Drug Substances for Final Drug Product Formulation of ADI-100 Ahead of Planned Clinical Trials in Type 1 Diabetes and Psoriasis in Germany, and Stiff Person Syndrome at the Mayo Clinic in the U.S. (Business Wire) -13.30%
Feb-22-25 08:45AM	Aditxt subsidiary Persanta engages Dominary Securities for IPO (TipRanks)
Feb-21-25 08:15AM	Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025 (Business Wire) -22.98%
Feb-13-25 08:15AM	Aditxt to Host Fireside Chat on Friday, February 21st at 11:30 AM Eastern Time (Business Wire) -17.87%
Jan-13-25 08:15AM	Aditxt's Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform (Business Wire) -8.24%
Dec-12-24 08:15AM	Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials (Business Wire)
Nov-19-24 07:17AM	Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc. (GlobeNewswire)
Nov-14-24 04:36PM	Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 (PR Newswire) -7.32%
07:15AM	Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025 (GlobeNewswire)
Nov-08-24 08:30AM	Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares (Business Wire)
Nov-07-24 08:30AM	Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders (Business Wire) -22.11%
Nov-06-24 05:55PM	Appili Therapeutics Announces Results of Special Meeting of Shareholders (GlobeNewswire)
08:30AM	Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem (Business Wire)
08:00AM	Evofem Secures Investor Support for Proposed Merger through Voting Agreements (PR Newswire)
Oct-31-24 08:30AM	Aditxts Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission (Business Wire)
07:15AM	Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission (GlobeNewswire)
Oct-30-24 05:00PM	Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time (Business Wire) -5.84%
Oct-29-24 08:15AM	Sylvia Hermina Joins Aditxt's Board of Directors, Elevating Leadership with Broader Perspectives (Business Wire) -18.07%
Oct-28-24 08:15AM	Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem (Business Wire) -14.72%
Oct-21-24 08:15AM	Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time (Business Wire)
Oct-12-24 05:28PM	Aditxt CEO Clarifies NASDAQ Compliance and Capital Strategy (TipRanks)
Oct-10-24 08:15AM	Aditxts Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appilis Shareholder Approval (Business Wire)
Oct-09-24 10:52AM	Aditxt To Host Stakeholder Update and Q&A Session on Friday, October 11, 2024, at 11:30 AM Eastern Daylight Time (Business Wire) -14.18%
Oct-08-24 08:15AM	Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem (Business Wire) -5.37%
Oct-03-24 08:15AM	Aditxt Delivers Shareholder Update and 2024 Year-End Plan (Business Wire) -28.15%
Sep-27-24 08:15AM	Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on October 2, 2024 (Business Wire) -25.60%
Sep-24-24 08:15AM	Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt (Business Wire) -15.87%
Sep-20-24 08:15AM	Aditxt's Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025 (Business Wire)
Sep-09-24 08:15AM	Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024 (Business Wire)
Sep-04-24 08:15AM	Aditxt Subsidiary Pearsanta Submits a Grant Application Seeking to Advance Clinical Trials for Mitomic Prostate Test, Targeting Early Detection in High-Risk Patients (Business Wire) -19.68%
Aug-29-24 08:15AM	Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024 (Business Wire) -7.64%
Aug-26-24 08:15AM	Aditxts Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic Endometriosis Test (MET) and Mitomic Prostate Test (MPT) (Business Wire) -11.70%
Aug-21-24 08:15AM	Aditxt Announces Third Amendment to Arrangement Agreement with Appili Therapeutics (Business Wire)
Aug-20-24 08:17AM	Evofem Biosciences Addresses the Impact of GLP-1 Medications on Oral Contraceptive Absorption and Introduces Phexxi as a Non-Oral Solution (PR Newswire) -16.67%
Aug-14-24 07:00AM	Evofem Biosciences Announces Financial Results for the Second Quarter of 2024 (PR Newswire)
Aug-13-24 08:15AM	Aditxt Announces the Successful Passage of all Proposals at Recent Annual Shareholders' Meeting, Setting the Stage for 2024 and 2025 Strategic Plans (Business Wire)
Aug-12-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) -11.38%
Aug-09-24 04:15PM	Aditxt Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules (Business Wire)
08:00AM	Aditxt Announces $1.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules (Business Wire)
Aug-07-24 08:15AM	Aditxt Subsidiary Pearsanta Seeks Clinical Trial Translational Endpoints Research Award for Early Detection of Ovarian Cancer (Business Wire) +29.39%
Jul-25-24 09:00AM	Evofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1st (GlobeNewswire)
08:30AM	Aditxt Signs Second Amendment to the Arrangement Agreement with Appili Therapeutics, Targeting September 30 Closing of the Acquisition (Business Wire)
Jul-23-24 08:47AM	Evofem Signs Phexxi License Agreement for Middle East with Pharma 1 (PR Newswire) +5.71%
Jul-17-24 06:30AM	Aditxt and Evofem Amend and Restate Merger Agreement, Targeting September 30 Closing (Business Wire) +45.01%
Jul-15-24 07:20AM	Lupin Divests U.S. Commercial Women's Health Specialty Business to Evofem, including SOLOSEC (PR Newswire) -6.21%
Jun-27-24 08:36AM	Hello Alpha Partners with Evofem to Offer Phexxi as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare (PR Newswire)
Jun-11-24 08:36AM	Evofem Announces Issuance of New U.S. Patent Covering Phexxi Composition of Matter (PR Newswire)
May-20-24 10:53PM	ADTX Stock Earnings: Aditxt Reported Results for Q1 2024 (InvestorPlace)

Aditxt, Inc. is a biotech innovation company, which engages in the development and commercialization of technologies focusing on monitoring and modulating the immune system. Its innovation portfolio includes Adimune and AditxtScore. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Mountain View, CA.

M.S.Dr. Shahrokh Shabahang D.D.S.

Chief Financial OfficerMr. Thomas J. Farley CPA

M.B.A.Ms. Corinne D. Pankovcin CPA

Interim Chief Executive OfficerMr. Jeffrey M. Busch J.D.

General Counsel & Chief People OfficerMr. Christopher J. Porcelli

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Takeover Time 2026 LLC	10% Owner	Jun 23 '26	Sale	0.02	3,420,439	68,409	0	Jun 25 07:06 PM
HRT FINANCIAL LP	10% Owner	Jun 18 '26	Buy	0.01	7,340,178	95,422	2,406,438	Jun 24 05:10 PM
HRT FINANCIAL LP	10% Owner	Jun 22 '26	Sale	0.02	5,120,480	92,169	0	Jun 24 05:10 PM
HRT FINANCIAL LP	10% Owner	Jun 16 '26	Sale	0.01	3,132,480	40,722	0	Jun 18 05:14 PM
DRW Securities, LLC	10% Owner	Jun 17 '26	Sale	0.01	126,772	1,001	0	Jun 18 12:18 PM
HRT FINANCIAL LP	10% Owner	Jun 12 '26	Buy	0.02	4,252,767	68,044	2,459,308	Jun 16 09:14 AM
BANK OF AMERICA CORP /DE/	10% Owner	Jun 11 '26	Buy	0.01	7	0	64	Jun 15 08:07 PM
BANK OF AMERICA CORP /DE/	10% Owner	Jun 11 '26	Sale	0.01	15	0	49	Jun 15 08:07 PM
HRT FINANCIAL LP	10% Owner	Jun 11 '26	Sale	0.01	2,833,463	39,668	0	Jun 12 03:33 PM
HRT FINANCIAL LP	10% Owner	Jun 08 '26	Buy	0.05	1,423,493	69,751	1,193,333	Jun 11 03:09 PM
HRT FINANCIAL LP	10% Owner	Jun 10 '26	Buy	0.02	725,330	13,781	1,040,004	Jun 11 03:09 PM
HRT FINANCIAL LP	10% Owner	Jun 09 '26	Sale	0.03	878,659	28,996	314,674	Jun 11 03:09 PM
Gong Sandie	10% Owner	Jun 09 '26	Sale	0.07	100,000	6,880	0	Jun 10 09:51 PM
HRT FINANCIAL LP	10% Owner	Jun 04 '26	Buy	0.08	843,622	64,115	505,302	Jun 08 06:19 PM
HRT FINANCIAL LP	10% Owner	Jun 05 '26	Sale	0.06	735,462	45,599	0	Jun 08 06:19 PM
HRT FINANCIAL LP	10% Owner	Apr 24 '26	Sale	0.28	29,404	8,233	88,377	Apr 27 03:13 PM
HRT FINANCIAL LP	10% Owner	Apr 23 '26	Sale	0.29	3,811	1,105	117,781	Apr 27 03:13 PM
HRT FINANCIAL LP	10% Owner	Apr 21 '26	Buy	0.33	72,912	24,061	133,574	Apr 23 03:43 PM
HRT FINANCIAL LP	10% Owner	Apr 22 '26	Sale	0.30	11,982	3,595	121,592	Apr 23 03:43 PM
Brady Brian Michael	Director	Dec 17 '25	Sale	1.75	1	2	3	Dec 19 05:00 PM
Pankovcin Corinne	Chief M&A Officer	Nov 25 '25	Sale	3.20	1	3	0	Nov 26 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ADTX

Aditxt Inc

Upgrade your Finviz experience